190 related articles for article (PubMed ID: 35523389)
1. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis.
Theofilis P; Antonopoulos AS; Katsimichas T; Oikonomou E; Siasos G; Aggeli C; Tsioufis K; Tousoulis D
Pharmacol Res; 2022 Jun; 180():106243. PubMed ID: 35523389
[TBL] [Abstract][Full Text] [Related]
2. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
Fan G; Guo DL
Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
[TBL] [Abstract][Full Text] [Related]
3. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function.
Shi FH; Li H; Shen L; Xu L; Ge H; Gu ZC; Lin HW; Pu J
J Clin Endocrinol Metab; 2022 Mar; 107(4):1191-1203. PubMed ID: 34791312
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.
Dhingra NK; Mistry N; Puar P; Verma R; Anker S; Mazer CD; Verma S
ESC Heart Fail; 2021 Dec; 8(6):4693-4700. PubMed ID: 34623032
[TBL] [Abstract][Full Text] [Related]
6. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
7. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
[TBL] [Abstract][Full Text] [Related]
8. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
9. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies.
Carluccio E; Biagioli P; Reboldi G; Mengoni A; Lauciello R; Zuchi C; D'Addario S; Bardelli G; Ambrosio G
Cardiovasc Diabetol; 2023 Sep; 22(1):235. PubMed ID: 37660005
[TBL] [Abstract][Full Text] [Related]
11. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
12. The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Usman MS; Januzzi JL; Anker SD; Salman A; Parikh PB; Adamo M; Filippatos G; Khan MS; Lala A; Verma S; Metra M; Butler J
Eur J Heart Fail; 2024 Feb; 26(2):373-382. PubMed ID: 38235936
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiac Imaging Parameters: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Wee CF; Teo YH; Teo YN; Syn NL; See RM; Leong S; Yip ASY; Ong ZX; Lee CH; Chan MY; Poh KK; Ong CC; Teo LL; Singh D; Tan BY; Yeo LL; Kong WK; Yeo TC; Wong RC; Chai P; Sia CH
J Cardiovasc Imaging; 2022 Jul; 30(3):153-168. PubMed ID: 35879251
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus.
Tanaka H; Hirata KI
Heart Fail Rev; 2018 May; 23(3):439-444. PubMed ID: 29330646
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium-glucose cotransporter protein-2 inhibitors on left ventricular hypertrophy in patients with type 2 diabetes: A systematic review and meta-analysis.
Wang Y; Zhong Y; Zhang Z; Yang S; Zhang Q; Chu B; Hu X
Front Endocrinol (Lausanne); 2022; 13():1088820. PubMed ID: 36699027
[TBL] [Abstract][Full Text] [Related]
18. Improvement of Global Longitudinal Strain and Myocardial Work in Type 2 Diabetes Patients on Sodium-Glucose Cotransporter 2 Inhibitors Therapy.
Russo V; Malvezzi Caracciolo D'Aquino M; Caturano A; Scognamiglio G; Pezzullo E; Fabiani D; Del Giudice C; Carbone A; Bottino R; Caso V; Nigro G; Golino P; Liccardo B; D'Andrea A
J Cardiovasc Pharmacol; 2023 Sep; 82(3):196-200. PubMed ID: 37405837
[TBL] [Abstract][Full Text] [Related]
19. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
Zhang Y; Yang D; Jia Q; Yan J; An F
Diabetes Obes Metab; 2024 Jun; 26(6):2401-2411. PubMed ID: 38528818
[TBL] [Abstract][Full Text] [Related]
20. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
